Last reviewed · How we verify
NCT04422379
COVID-19 and Liver Injury in Patients With or Without Underlying Liver Disease: A Multi-centre Retrospective-prospective Observational Study
trial in COVID-19 in 314 participants. Status unknown.
30 July 2020
Quick facts
| Lead sponsor | Max Healthcare Insititute Limited |
|---|---|
| Status | Status unknown |
| Study type | OBSERVATIONAL |
| Enrollment | 314 |
| Start date | 7 June 2020 |
| Primary completion | 30 July 2020 |
| Estimated completion | 30 August 2020 |
| Sites | 1 location across India |
Conditions studied
- COVID-19 — all drugs for COVID-19 →
Sponsor
Max Healthcare Insititute Limited
Who can join
Adults 18 to 75, any sex, with COVID-19. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
COVID-19 and liver injury in patients with or without underlying liver disease: A multi-centre retrospective-prospective observational study. All patients infected with SARS-CoV-2 and admitted to the COVID-19 ward/ICU of Max Hospital Saket (either in East Wing , Max Super Specialty Hospital, Saket or MAX Smart Super Specialty Hospital, Saket) between 1/4/2020 to 30/6/2020 (retrospective data between 1/4/2020- 30/5/2020 \& prospective data from approval till 30/6/2020), will be included
Publications & conference data
No peer-reviewed publications indexed yet for this trial.
Verify or expand the search:
- PubMed search for NCT04422379
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for COVID-19
Currently open trials in the same condition.
- NCT07183709 — Safety and Immunogenicity Trial of PepGNP-COVID19 Vaccine in Adults · Phase 1 · active not recruiting
- NCT07300839 — A Study to Learn About a COVID-19 Vaccine in Healthy Adults 50 Through 64 Years of Age · Phase 3 · active not recruiting
- NCT07221162 — A Safety and Immunogenicity Trial of Boost-2867 Vaccine, Via Intranasal and Intramuscular Routes · Phase 1 · recruiting
- NCT07215520 — Safety and Tolerability of a Newcastle Disease Virus-Based Mucosal COVID-19 Vaccine in Previously Vaccinated Adults · Phase 2 · recruiting
- NCT07222384 — A Study to Learn About BNT162b2 (LP.8.1)-Adapted Vaccine Against SARS-CoV-2 in Children 5 Through 11 Years of Age That A · Phase 3 · active not recruiting
Other Max Healthcare Insititute Limited trials
Trials by the same sponsor.
- NCT07496333 — The Effect of Virtual Reality Distraction on Pain During Colonoscopy · NA · completed
- NCT06456216 — Performance Evaluation of Diagnostic Accuracy of PanTum Detect Test for Detection of Solid Tumours in Known Cancer Popul · completed
- NCT04469660 — Impact of COVID-19 Pandemic on the Psychological Wellbeing of Healthcare Professionals in India · unknown
- NCT04374487 — Assess the Safety and Efficacy of Convalescent Plasma to Limit COVID-19 Associated Complications · Phase 2 · unknown
- NCT04406844 — Issues and Challenges in Cancer Patients on Active Treatment During the COVID-19 Pandemic · unknown
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT04422379 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Max Healthcare Insititute Limited
- Last refreshed: 9 June 2020
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04422379.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing